TBC 3711

Drug Profile

TBC 3711

Alternative Names: TBC3711

Latest Information Update: 14 Sep 2010

Price : $50

At a glance

  • Originator Encysive Pharmaceuticals
  • Class Anti-ischaemics; Heart failure therapies; Isoxazoles; Small molecules; Thiophenes
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Resistant hypertension

Most Recent Events

  • 11 Jun 2008 Encysive Pharmaceuticals has been acquired by Pfizer
  • 21 Mar 2007 Phase-II clinical trials in Resistant hypertension in USA (PO)
  • 12 Dec 2006 Phase-I clinical trials in Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top